BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Guo Y, Jiang Y, Rose JB, Nagaraju GP, Jaskula-Sztul R, Hjelmeland AB, Beck AW, Chen H, Ren B. Protein Kinase D1 Signaling in Cancer Stem Cells with Epithelial-Mesenchymal Plasticity. Cells 2022;11. [PMID: 36497140 DOI: 10.3390/cells11233885] [Reference Citation Analysis]
2 Rao BH, Souček P, Hlaváč V. Laser Capture Microdissection: A Gear for Pancreatic Cancer Research. Int J Mol Sci 2022;23. [PMID: 36498893 DOI: 10.3390/ijms232314566] [Reference Citation Analysis]
3 Исянгулова АЗ, Гордиев МГ. Молекулярный профиль нейроэндокринных опухолей. Zlokač opuholi 2022;12:9-16. [DOI: 10.18027/2224-5057-2022-12-3s1-9-16] [Reference Citation Analysis]
4 Gulde S, Foscarini A, April-Monn SL, Genio E, Marangelo A, Satam S, Helbling D, Falconi M, Toledo RA, Schrader J, Perren A, Marinoni I, Pellegata NS. Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. Cancers (Basel) 2022;14. [PMID: 36428573 DOI: 10.3390/cancers14225481] [Reference Citation Analysis]
5 Smolkova B, Kataki A, Earl J, Ruz-caracuel I, Cihova M, Urbanova M, Buocikova V, Tamargo S, Rovite V, Niedra H, Schrader J, Kohl Y. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103865] [Reference Citation Analysis]
6 Ciobanu OA, Martin SC, Herlea V, Fica S. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup. Cancers 2022;14:4444. [DOI: 10.3390/cancers14184444] [Reference Citation Analysis]
7 Gubbi S, Vijayvergia N, Yu JQ, Klubo-Gwiezdzinska J, Koch CA. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Horm Metab Res 2022;54:795-812. [PMID: 35878617 DOI: 10.1055/a-1908-7790] [Reference Citation Analysis]
8 Pedraza-Arevalo S, Alors-Pérez E, Blázquez-Encinas R, Herrera-Martínez AD, Jiménez-Vacas JM, Fuentes-Fayos AC, Reyes Ó, Ventura S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Gálvez-Moreno MA, Gahete MD, Ibáñez-Costa A, Luque RM, Castaño JP. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. Transl Res 2022:S1931-5244(22)00170-0. [PMID: 35882361 DOI: 10.1016/j.trsl.2022.07.005] [Reference Citation Analysis]
9 Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, Palo L, Giordano A, Incoronato M, Vitale M, Mian C, Di Biase I, Cristiano S, Narciso V, Cantile M, Di Mauro A, Tatangelo F, Tafuto S, Modica R, Pivonello C, Salvatore M, Colao A, Weisz A, Tarallo R. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03511-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ramya Devi KT, Karthick D, Saravanaraj KS, Jaganathan MK, Ghorai S, Hemdev SP. The roles of microRNA in pancreatic cancer progression. Cancer Invest 2022;:1-26. [PMID: 35333689 DOI: 10.1080/07357907.2022.2057526] [Reference Citation Analysis]
11 de Sousa MJ, Gervaso L, Meneses-Medina MI, Spada F, Abdel-Rahman O, Fazio N. Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside. Curr Oncol Rep 2022. [PMID: 35262877 DOI: 10.1007/s11912-022-01251-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Guo Y, Jiang Y, Rose JB, Jaskula-sztul R, Hjelmeland AB, Chen H, Ren B. PKD-1 Signaling Is Required for the Maintenance of CSCs with Epithelial-mesenchymal Plasticity in Pancreatic Neuroendocrine Tumors.. [DOI: 10.1101/2022.02.17.480869] [Reference Citation Analysis]
14 Pedraza-arevalo S, Alors-pérez E, Blázquez-encinas R, Herrera-martínez AD, Jiménez-vacas JM, Fuentes-fayos AC, Reyes Ó, Ventura S, Sánchez-sánchez R, Ortega-salas R, Serrano-blanch R, Gálvez-moreno MA, Gahete MD, Ibáñez-costa A, Luque RM, Castaño JP. Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors.. [DOI: 10.1101/2022.02.09.479525] [Reference Citation Analysis]
15 Coco D, Leanza S. Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective. J Kidney Cancer VHL 2022;9:27-32. [PMID: 34963877 DOI: 10.15586/jkcvhl.v9i1.206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Chen J, Wang P, Lv K, Zhou W. Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm? Diagn Pathol 2021;16:108. [PMID: 34801052 DOI: 10.1186/s13000-021-01165-5] [Reference Citation Analysis]